Epidermal growth factor receptor (EGFR) mutations activated in non-small cell lung cancer (NSCLC) are effective targets for EGFR tyrosine kinase inhibitors (TKIs) (Zhou et al., 2011). Here, EGFR is linked to non-small cell lung carcinoma.